Journal article

Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies

Laura A Rabin, Colette M Smart, Paul K Crane, Rebecca E Amariglio, Lorin M Berman, Merce Boada, Rachel F Buckley, Gael Chetelat, Bruno Dubois, Kathryn A Ellis, Katherine A Gifford, Angela L Jefferson, Frank Jessen, Mindy J Katz, Richard B Lipton, Tobias Luck, Paul Maruff, Michelle M Mielke, Jose Luis Molinuevo, Farnia Naeem Show all



Research increasingly suggests that subjective cognitive decline (SCD) in older adults, in the absence of objective cognitive dysfunction or depression, may be a harbinger of non-normative cognitive decline and eventual progression to dementia. Little is known, however, about the key features of self-report measures currently used to assess SCD. The Subjective Cognitive Decline Initiative (SCD-I) Working Group is an international consortium established to develop a conceptual framework and research criteria for SCD (Jessen et al., 2014, Alzheimers Dement 10, 844-852). In the current study we systematically compared cognitive self-report items used by 19 SCD-I Working Group studies, represent..

View full abstract


Awarded by National Institutes of Health (NIA/NIGMS)

Awarded by PSC-CUNY

Awarded by Alzheimer Society of Canada

Awarded by National Institute on Aging (NIA)

Awarded by NIH

Awarded by Alzheimer's Association

Awarded by National Institutes of Health

Awarded by German Federal Ministry of Education and Research

Awarded by National Institute on Aging (NIA/NIH)

Awarded by Miguel Servet II grant from the Spanish Ministry of Science

Awarded by NIA

Awarded by Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health)

Awarded by DOD ADNI (Department of Defense)

Awarded by Alzheimer Nederland




Funding Acknowledgements

LAR was supported by the National Institutes of Health (NIA/NIGMS grant SC2AG039235) and PSC-CUNY (Award #68859-00 46); CMS was supported by the Alzheimer Society of Canada (Young Investigator Award #1216); PKC was supported by the National Institute on Aging (NIA) grants U01 AG 006781 (E Larson, PI) and R01 AG 042437 (P Crane, PI); REA was supported by NIH grant K23AG044431 and Alzheimer's Association grant NIRG-12-243012; RFB was supported by Alzheimer's Australia Dementia Research Foundation (Postdoctoral Fellowship); GC and AP report the following sources of financial support and funding: Fondation Plan Alzheimer (Alzheimer Plan 2008-2012), Programme Hospitalier de Recherche Clinique (PHRC National 2011, complement PHRC 2012), Agence Nationale de la Recherche (ANR LONGVIE 2007), Region Basse Normandie, and Institut National de la Sante et de la Recherche Medicale (Inserm); BD and CT (PreAl study) were supported by the national Programme Hospitalier de Recherche Clinique; KE, PM, and RFB (AIBL study) were supported by Commonwealth Scientific and Industrial Research Organisation (CSIRO), the Science and Industry Endowment Fund (, the National Health and Medical Research Council (NHMRC), and Dementia Collaborative Research Centres (DCRC), as well as industry, including Pfizer, Merck, Janssen, and GE Healthcare; MJK and RBL were supported, in part by National Institutes of Health grants NIA 2 P01 AG03949 and NIA R03 AG045474, the Leonard and Sylvia Marx Foundation, and the Czap Foundation; TL was supported by the Study on Needs, Health Service Use, Costs and Health-related Quality of Life in a large Sample of Oldest-old Primary Care Patients (85+) AgeQualiDe; funded by the German Federal Ministry of Education and Research Grant 01GY1322A; BR was supported by National Institute on Aging (NIA/NIH) grants P30 AG08051 and AG03051 and by the Stringer Foundation, the Louis and June Kay Foundation, the Hagedorn Fund, and gifts from Dr. Felix and Mrs. Miriam Glaubach; LR is the recipient of a Miguel Servet II grant as a senior investigator from the Spanish Ministry of Science (CP2/00023); SLR was supported by NIA grants R01 AG19771, NIA P30 AG10133, the Alzheimer's Association, the Indiana University Health-Indiana University School of Medicine Strategic Research Initiative, and the Indiana Clinical and Translational Science Institute; RAS and DMR were supported by NIH grants P01AG036694, R01 AG027435, K24 AG035007, and U19 AG10483; BES was supported by National Institutes of Health grants K23AG038479, R01 AG023651, P01 AG025204, and R37 AG025516; AJS was supported by grants: NIA R01 AG19771, NIA P30 AG10133, and R01 LM011360; ADNI data and sharing was funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego; SAMS was supported by Stichting VUmc fonds, the Innovatiefonds Zorgverzekeraars, and a fellowship program from Alzheimer Nederland (WE. 15-2012-02).